NO2024001I1 - Ritlecitinib, or a pharmaceutically acceptable salt thereof - Google Patents

Ritlecitinib, or a pharmaceutically acceptable salt thereof

Info

Publication number: NO2024001I1
Authority: NO; Norway
Prior art keywords: ritlecitinib; pharmaceutically acceptable; acceptable salt; salt; pharmaceutically
Prior art date: 2013-12-05

Application number

NO2024001C

Other languages

English (en)

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-05

Filing date

2024-01-09

Publication date

2024-01-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52144776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2024001(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2024-01-09 Application filed by Pfizer filed Critical Pfizer

2024-01-09 Publication of NO2024001I1 publication Critical patent/NO2024001I1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Transplantation (AREA)

NO2024001C 2013-12-05 2024-01-09 Ritlecitinib, or a pharmaceutically acceptable salt thereof NO2024001I1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361912074P	2013-12-05	2013-12-05
PCT/IB2014/066202 WO2015083028A1 (en)	2013-12-05	2014-11-20	Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

Publications (1)

Publication Number	Publication Date
NO2024001I1 true NO2024001I1 (no)	2024-01-09

Family

ID=52144776

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO15721089A NO3134430T3 (no)	2013-12-05	2015-04-23
NO2024001C NO2024001I1 (no)	2013-12-05	2024-01-09	Ritlecitinib, or a pharmaceutically acceptable salt thereof

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO15721089A NO3134430T3 (no)	2013-12-05	2015-04-23

Country Status (47)

Country	Link
US (3)	US9617258B2 (no)
EP (2)	EP3318565B1 (no)
JP (2)	JP6192839B2 (no)
KR (1)	KR101930603B1 (no)
CN (2)	CN106061973B (no)
AP (1)	AP2016009269A0 (no)
AR (1)	AR099363A1 (no)
AU (1)	AU2014358792C1 (no)
BR (1)	BR112016012262B1 (no)
CA (1)	CA2932425C (no)
CL (1)	CL2016001216A1 (no)
CR (1)	CR20160250A (no)
CU (1)	CU24396B1 (no)
CY (3)	CY1119778T1 (no)
DK (2)	DK3077395T3 (no)
DO (1)	DOP2016000124A (no)
EA (1)	EA030472B1 (no)
ES (2)	ES2871524T3 (no)
FI (1)	FIC20230035I1 (no)
FR (1)	FR23C1042I2 (no)
GE (1)	GEP20186840B (no)
GT (1)	GT201600098A (no)
HR (2)	HRP20171846T1 (no)
HU (3)	HUE054560T2 (no)
IL (1)	IL246038B (no)
LT (2)	LT3318565T (no)
MA (1)	MA39092B1 (no)
MD (1)	MD4649C1 (no)
ME (1)	ME02883B (no)
MX (1)	MX368464B (no)
MY (1)	MY187446A (no)
NI (1)	NI201600075A (no)
NL (1)	NL301245I2 (no)
NO (2)	NO3134430T3 (no)
NZ (1)	NZ720092A (no)
PE (1)	PE20161246A1 (no)
PH (1)	PH12016500938B1 (no)
PL (2)	PL3077395T3 (no)
PT (2)	PT3077395T (no)
RS (2)	RS56728B1 (no)
SI (2)	SI3077395T1 (no)
SV (1)	SV2016005209A (no)
TN (1)	TN2016000227A1 (no)
TW (1)	TWI548636B (no)
UA (1)	UA117040C2 (no)
UY (1)	UY35861A (no)
WO (1)	WO2015083028A1 (no)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112016005881A2 (pt)	2013-09-18	2017-09-12	Beijing Hanmi Pharmaceutical Co Ltd	composto, composição farmacêutica e uso do composto
HUE054560T2 (hu) *	2013-12-05	2021-09-28	Pfizer	Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil és pirrolo[2,3-d]piridinil akrilamidok
WO2016000615A1 (en) *	2014-07-02	2016-01-07	Sunshine Lake Pharma Co., Ltd.	Heteroaryl compounds and pharmaceutical applications thereof
ES2893289T3 (es)	2014-08-28	2022-02-08	Asceneuron Sa	Inhibidores de glucosidasa
CN105712998B (zh) *	2014-12-05	2019-12-13	上海润诺生物科技有限公司	氮杂吲哚类衍生物、其制备方法及其在医药上的应用
CA2973597A1 (en) *	2015-01-23	2016-07-28	Confluence Life Sciences, Inc.	Heterocyclic itk inhibitors for treating inflammation and cancer
CN105837574B (zh) *	2015-02-02	2018-03-02	四川大学	N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
JP6761815B2 (ja) *	2015-05-01	2020-09-30	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、ピロロ［２，３−ｂ］ピリジニルアクリルアミド、およびそのエポキシド
AU2016271904B2 (en) *	2015-05-29	2018-05-10	Wuxi Fortune Pharmaceutical Co.,Ltd	Janus kinase inhibitor
CN106432246B (zh) *	2015-08-05	2020-07-07	广东东阳光药业有限公司	杂芳化合物及其在药物中的应用
KR101771219B1 (ko) *	2015-08-21	2017-09-05	양지화학 주식회사	야누스 키나제 1 선택적 억제제 및 그 의약 용도
EP3371186A1 (en)	2015-11-03	2018-09-12	Theravance Biopharma R&D IP, LLC	Jak kinase inhibitor compounds for treatment of respiratory disease
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CN108884077A (zh)	2016-02-25	2018-11-23	阿森纽荣股份公司	糖苷酶抑制剂
AU2017222962B2 (en)	2016-02-25	2021-03-25	Asceneuron S. A.	Acid addition salts of piperazine derivatives
CA3012624A1 (en)	2016-02-25	2017-08-31	Asceneuron S.A.	Glycosidase inhibitors
US11261183B2 (en)	2016-02-25	2022-03-01	Asceneuron Sa	Sulfoximine glycosidase inhibitors
PE20190811A1 (es) *	2016-06-30	2019-06-13	Dae Woong Pharma	Derivados de pirazolopirimidinas como inhibidor de quinasa
WO2018039310A1 (en)	2016-08-24	2018-03-01	Arqule, Inc.	Amino-pyrrolopyrimidinone compounds and methods of use thereof
MX391179B (es) *	2016-11-23	2025-03-21	Jiangsu Hengrui Medicine Co	Método de preparación e intermediario de derivado de un anillo heteroaromático de seis miembros pirrolo
CA3033456C (en) *	2016-11-23	2021-03-09	Wuxi Fortune Pharmaceutical Co., Ltd	Crystal forms and salt forms of 7h-pyrrolo[2,3-d]pyrimidine compounds and preparation method thereof
CN110291090A (zh) *	2017-01-20	2019-09-27	利奥制药有限公司	作为新型jak激酶抑制剂的双环胺
CA3045745A1 (en)	2017-02-27	2018-08-30	Janssen Pharmaceutica Nv	[1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazin as oga inhibitors
EA037748B1 (ru)	2017-03-09	2021-05-18	ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи	Конденсированные имидазо-пиперидиновые ингибиторы jak
CN108794480A (zh) *	2017-04-28	2018-11-13	天津药物研究院有限公司	吡咯并嘧啶类化合物、其制备方法和用途
AU2018261591B2 (en)	2017-05-01	2021-09-02	Theravance Biopharma R&D Ip, Llc	Crystalline forms of a JAK inhibitor compound
US10406148B2 (en)	2017-05-01	2019-09-10	Theravance Biopharma R&D Ip, Llc	Methods of treatment using a JAK inhibitor compound
AR111495A1 (es)	2017-05-01	2019-07-17	Theravance Biopharma R&D Ip Llc	Compuestos de imidazo-piperidina fusionada como inhibidores de jak
EP3652169A1 (en)	2017-08-01	2020-05-20	Theravance Biopharma R&D IP, LLC	Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
WO2019037860A1 (en)	2017-08-24	2019-02-28	Asceneuron S.A.	LINEAR INHIBITORS OF GLYCOSIDASE
EP3710431A4 (en)	2017-11-03	2021-07-07	Aclaris Therapeutics, Inc.	SUBSTITUTED PYRROLOPYRIMIDINE-BASED JAK INHIBITORS AND THEIR MANUFACTURING AND USE PROCEDURES
CA3079848A1 (en) *	2017-11-07	2019-05-16	The Regents Of The University Of Michigan	Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
CN107857778B (zh) *	2017-11-21	2020-03-24	江苏乐斯化学有限公司	含膦酰基的α-氨基腈的制备方法
KR102577241B1 (ko) *	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko)	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
LT3733673T (lt) *	2017-12-28	2022-08-10	Daewoong Pharmaceutical Co., Ltd.	Oksi-fluorpiperidino darinys, kaip kinazės inhibitorius
CA3093706A1 (en) *	2018-03-21	2019-09-26	Xibin Liao	Jak inhibitors
CN108358797A (zh) *	2018-04-20	2018-08-03	南京农业大学	一种烷基甘氨酸的合成方法
CN108640923A (zh) *	2018-07-09	2018-10-12	湖南天地恒制药有限公司	一种托法替布关键中间体的制备方法
AU2019316858B2 (en)	2018-08-06	2024-03-28	Moexa Pharmaceuticals Limited	Smad3 inhibitors
JP7591500B2 (ja) *	2018-08-10	2024-11-28	アクラリスセラピューティクス，インコーポレイテッド	ピロロピリミジンｉｔｋ阻害剤
MA53429A (fr)	2018-08-22	2022-03-30	Asceneuron Sa	Sels d'addition d'acide succinate et fumarate de dérivés de pipérazine utiles en tant qu'inhibiteurs de glycosidase
WO2020039029A1 (en)	2018-08-22	2020-02-27	Asceneuron S. A.	Spiro compounds as glycosidase inhibitors
US11795165B2 (en)	2018-08-22	2023-10-24	Asceneuron Sa	Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039027A1 (en)	2018-08-22	2020-02-27	Asceneuron S. A.	Pyrrolidine glycosidase inhibitors
BR112021004087A2 (pt)	2018-09-04	2021-05-25	Theravance Biopharma R&D Ip, Llc	processo para preparar inibidores de jak e seus intermediários
WO2020051105A1 (en)	2018-09-04	2020-03-12	Theravance Biopharma R&D Ip, Llc	Dimethyl amino azetidine amides as jak inhibitors
JP7383696B2 (ja)	2018-09-04	2023-11-20	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	Ｊａｋ阻害剤としての５員～７員の複素環アミド
WO2020067887A1 (en)	2018-09-24	2020-04-02	Erasmus University Medical Center Rotterdam	Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
JP6944496B2 (ja) *	2018-10-22	2021-10-06	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
EP3853229A1 (en)	2018-10-29	2021-07-28	Theravance Biopharma R&D IP, LLC	2-azabicyclo hexane compound as jak inhibitor
WO2020154350A1 (en)	2019-01-23	2020-07-30	Theravance Biopharma R&D Ip, Llc	Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
EP3939979A4 (en) *	2019-03-14	2022-04-06	Shanghai Synergy Pharmaceutical Sciences Co., Ltd	KINASE JAK INHIBITOR, METHOD FOR PREPARING IT AND ITS APPLICATIONS IN THE FIELD OF MEDICINE
CN113993585B (zh) *	2019-03-27	2024-10-01	英矽智能科技知识产权有限公司	双环jak抑制剂及其用途
CA3138544A1 (en) *	2019-05-02	2020-11-05	Aclaris Therapeutics, Inc.	Substituted pyrrolopyridines as jak inhibitors
EP3969458A4 (en)	2019-05-13	2023-05-17	Borah, Inc.	CHEMICAL COMPOUNDS
KR102503349B1 (ko)	2019-05-14	2023-02-23	프로벤션 바이오, 인코포레이티드	제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN110183455B (zh) *	2019-06-18	2021-04-20	中国医科大学	氮杂双环[3.2.1]辛-3-酮类化合物及其制备方法与其用途
CN112430235B (zh) *	2019-08-26	2024-04-05	东莞市东阳光仿制药研发有限公司	一种pf-06651600中间体的制备方法
KR102228668B1 (ko)	2019-10-08	2021-03-17	(주)부흥산업사	메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법
US20220378707A1 (en)	2019-11-14	2022-12-01	Pfizer Inc.	1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
CN112824381B (zh) *	2019-11-21	2024-04-26	广东东阳光药业股份有限公司	一种哌啶胺的制备方法
CN113121413B (zh) *	2019-12-31	2024-04-09	江苏艾立康医药科技有限公司	一种jak3酶抑制剂关键中间体的制备方法
CN113121539A (zh) *	2019-12-31	2021-07-16	江苏艾立康医药科技有限公司	一种pf06651600的制备方法
CA3166050C (en) *	2019-12-31	2024-02-20	Pfizer R&D Uk Limited	Stable immediate release tablet and capsule formulations of 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
CN111138361B (zh) *	2020-01-03	2022-05-06	中国医科大学	取代苯氧基-2-氮杂双环[3.2.1]辛烷类化合物及其制备方法和应用
WO2021147953A1 (zh) *	2020-01-21	2021-07-29	江苏先声药业有限公司	嘧啶并五元环类衍生物及其应用
TW202144343A (zh)	2020-03-02	2021-12-01	美商施萬生物製藥研發 Ip有限責任公司	Jak抑制劑化合物之結晶水合物
AU2021248720A1 (en)	2020-04-04	2022-11-03	Pfizer Inc.	Methods of treating coronavirus disease 2019
IL298999A (en)	2020-06-11	2023-02-01	Provention Bio Inc	Methods and compositions for preventing type 1 diabetes
CN114835715B (zh) *	2020-06-15	2024-04-05	江苏艾立康医药科技有限公司	Pf-06651600马来酸盐及其制备方法
CN111620880B (zh) *	2020-06-15	2022-06-10	江苏艾立康医药科技有限公司	Pf-06651600 dl-酒石酸盐，晶型及其制备方法
WO2022002210A1 (zh) *	2020-07-02	2022-01-06	南京明德新药研发有限公司	嘧啶并吡咯基类氘代化合物
WO2022012587A1 (zh) *	2020-07-14	2022-01-20	苏州晶云药物科技股份有限公司	丙烯酮类化合物的丙二酸盐晶型及其制备方法
CN111995623A (zh) *	2020-08-18	2020-11-27	上海毕得医药科技有限公司	一种7-溴-4-氯-1-甲基-1H-咪唑并[4,5-c]吡啶的合成方法
KR102473645B1 (ko)	2020-08-28	2022-12-05	(주)부흥산업사	(2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법
CN113061137B (zh) *	2021-04-02	2022-08-02	广西医科大学	含氮杂环衍生物或其药学上可接受的盐和用途
CN113429427A (zh) *	2021-07-05	2021-09-24	湖南南新制药股份有限公司	杂环化合物及其制备方法和药物用途
KR20240051146A (ko) *	2021-08-25	2024-04-19	항저우 위홍 파마테크 컴퍼니 리미티드	방향족 헤테로고리 화합물, 이를 함유한 약물 조성물 및 이의 응용
WO2023029943A1 (zh) *	2021-09-03	2023-03-09	星药科技(北京)有限公司	一种芳杂环化合物及其制备方法和用途
WO2023151069A1 (zh) *	2022-02-14	2023-08-17	湖南南新制药股份有限公司	吡咯并[2,3-d]六元杂芳环衍生物、其制备方法和药物用途
WO2024084363A1 (en)	2022-10-18	2024-04-25	Pfizer Inc.	Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024084360A1 (en)	2022-10-18	2024-04-25	Pfizer Inc.	Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024150110A1 (en)	2023-01-11	2024-07-18	Pfizer Inc.	Compositions and methods for the treatment and/or prevention of type 1 diabetes
CN116120347B (zh) *	2023-01-18	2024-08-23	杭州禹泓医药科技有限公司	芳杂环类化合物的晶型、其组合物、制备方法及其应用
CN116496280B (zh) *	2023-06-25	2023-09-08	北京科翔中升医药科技有限公司	氘代丙烯酰胺类jak3抑制剂药物及用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8474101A1 (es) *	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
BR9911365A (pt)	1998-06-19	2001-03-13	Pfizer Prod Inc	Compostos pirrolo[2,3-d]pirimidina
EA006227B1 (ru)	1999-12-10	2005-10-27	Пфайзер Продактс Инк.	СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
EE200200711A (et) *	2000-06-26	2004-06-15	Pfizer Products Inc.	Pürrolo[2,3-d]pürimidiinühendid kui immunosupressiivsed vahendid
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
RS20050380A (en)	2002-11-21	2007-11-15	Pfizer Products Inc.,	3-amino piperidine derivatives and methods of manufacture
AR054416A1 (es) *	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CN102127078A (zh)	2005-07-14	2011-07-20	安斯泰来制药株式会社	Janus激酶3的杂环类抑制剂
SI1913000T1 (sl)	2005-07-29	2012-02-29	Pfizer Prod Inc	Derivati pirolo(2,3-d)pirimidina; njihovi intermediati in sinteza
WO2007062459A1 (en)	2005-11-29	2007-06-07	Cytopia Research Pty Ltd	Selective kinase inhibitors based on pyridine scaffold
SI1966202T1 (sl)	2005-12-13	2012-01-31	Incyte Corp	S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
PL2529622T3 (pl)	2006-09-22	2018-07-31	Pharmacyclics Llc	Inhibitory kinazy tyrozynowej brutona
JO3041B1 (ar)	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
ATE542813T1 (de)	2008-08-06	2012-02-15	Pfizer	6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
CA2735937A1 (en)	2008-09-05	2010-03-11	Avila Therapeutics, Inc.	Algorithm for designing irreversible inhibitors
PE20110828A1 (es)	2008-10-31	2011-11-22	Genentech Inc	Compuestos de pirazolopirimidina como inhibidores de jak
SG171956A1 (en)	2008-12-05	2011-07-28	Hoffmann La Roche	Pyrrolopyrazinyl urea kinase inhibitors
JOP20190231A1 (ar)	2009-01-15	2017-06-16	Incyte Corp	طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
ES2659725T3 (es) *	2009-05-05	2018-03-19	Dana-Farber Cancer Institute, Inc.	Inhibidores de EGFR y procedimiento de tratamiento de trastornos
JO3030B1 (ar)	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2881034B1 (en)	2009-06-30	2020-06-10	Edwards Lifesciences Corporation	Monitoring and displaying a patient's status
UA110324C2 (en)	2009-07-02	2015-12-25	Genentech Inc	Jak inhibitory compounds based on pyrazolo pyrimidine
CN102574857B (zh) *	2009-07-08	2015-06-10	利奥制药有限公司	作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物
WO2011014930A1 (en)	2009-08-07	2011-02-10	Metaleach Limited	Method for leaching cobalt from oxidised cobalt ores
CN102711473B (zh)	2009-09-04	2016-11-09	比奥根Ma公司	布鲁顿酪氨酸激酶抑制剂
ES2642109T3 (es)	2009-12-09	2017-11-15	Agios Pharmaceuticals, Inc.	Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
RU2012152352A (ru) *	2010-05-20	2014-06-27	Ф. Хоффманн-Ля Рош Аг	ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРАЗИН-7-КАРБОКСАМИДА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ JAK И SYK
WO2012003829A1 (en)	2010-07-09	2012-01-12	Leo Pharma A/S	Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
US8937077B2 (en) *	2010-10-22	2015-01-20	Merck Sharp & Dohme Corp.	Bicyclic diamines as janus kinase inhibitors
US8993756B2 (en) *	2011-12-06	2015-03-31	Merck Sharp & Dohme Corp.	Pyrrolopyrimidines as janus kinase inhibitors
KR102032934B1 (ko)	2011-12-21	2019-10-16	지앙수 헨그루이 메디슨 컴퍼니 리미티드	피롤 6원 헤테로아릴 고리 유도체, 그의 제조 방법, 및 그의 의약 용도
US10227357B2 (en) *	2012-09-06	2019-03-12	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
MX2015006191A (es)	2012-11-16	2015-08-10	Merck Sharp & Dohme	Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana.
SG11201503977PA (en)	2012-11-20	2015-06-29	Principia Biopharma Inc	Azaindole derivatives as jak3 inhibitors
CN103896946B (zh) *	2012-12-28	2018-04-03	浙江导明医药科技有限公司	用于预防及治疗多种自身免疫疾病的新化合物
HUE054560T2 (hu) *	2013-12-05	2021-09-28	Pfizer	Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil és pirrolo[2,3-d]piridinil akrilamidok
WO2015178955A1 (en) *	2014-05-19	2015-11-26	Eternity Bioscience Inc.	Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors

2014
- 2014-11-20 HU HUE17200940A patent/HUE054560T2/hu unknown
- 2014-11-20 PE PE2016000723A patent/PE20161246A1/es unknown
- 2014-11-20 HU HUE14816404A patent/HUE035264T2/hu unknown
- 2014-11-20 MA MA39092A patent/MA39092B1/fr unknown
- 2014-11-20 SI SI201430511T patent/SI3077395T1/en unknown
- 2014-11-20 BR BR112016012262-3A patent/BR112016012262B1/pt active IP Right Grant
- 2014-11-20 CN CN201480074974.2A patent/CN106061973B/zh active Active
- 2014-11-20 MD MDA20160058A patent/MD4649C1/ro active IP Right Grant
- 2014-11-20 GE GEAP201414164A patent/GEP20186840B/en unknown
- 2014-11-20 NZ NZ720092A patent/NZ720092A/en unknown
- 2014-11-20 MY MYPI2016702037A patent/MY187446A/en unknown
- 2014-11-20 DK DK14816404.9T patent/DK3077395T3/en active
- 2014-11-20 JP JP2016536110A patent/JP6192839B2/ja active Active
- 2014-11-20 LT LTEP17200940.9T patent/LT3318565T/lt unknown
- 2014-11-20 CR CR20160250A patent/CR20160250A/es unknown
- 2014-11-20 ES ES17200940T patent/ES2871524T3/es active Active
- 2014-11-20 RS RS20180008A patent/RS56728B1/sr unknown
- 2014-11-20 ME MEP-2017-275A patent/ME02883B/me unknown
- 2014-11-20 EP EP17200940.9A patent/EP3318565B1/en active Active
- 2014-11-20 MX MX2016007156A patent/MX368464B/es active IP Right Grant
- 2014-11-20 RS RS20210657A patent/RS61897B9/sr unknown
- 2014-11-20 WO PCT/IB2014/066202 patent/WO2015083028A1/en active Application Filing
- 2014-11-20 UA UAA201606072A patent/UA117040C2/uk unknown
- 2014-11-20 ES ES14816404.9T patent/ES2654051T3/es active Active
- 2014-11-20 CU CU2016000077A patent/CU24396B1/es unknown
- 2014-11-20 SI SI201431829T patent/SI3318565T1/sl unknown
- 2014-11-20 PL PL14816404T patent/PL3077395T3/pl unknown
- 2014-11-20 DK DK17200940.9T patent/DK3318565T3/da active
- 2014-11-20 AU AU2014358792A patent/AU2014358792C1/en active Active
- 2014-11-20 TN TN2016000227A patent/TN2016000227A1/fr unknown
- 2014-11-20 KR KR1020167017571A patent/KR101930603B1/ko active Active
- 2014-11-20 AP AP2016009269A patent/AP2016009269A0/en unknown
- 2014-11-20 CN CN201710579812.XA patent/CN107417684A/zh active Pending
- 2014-11-20 LT LTEP14816404.9T patent/LT3077395T/lt unknown
- 2014-11-20 CA CA2932425A patent/CA2932425C/en active Active
- 2014-11-20 EA EA201600373A patent/EA030472B1/ru unknown
- 2014-11-20 PT PT148164049T patent/PT3077395T/pt unknown
- 2014-11-20 PT PT172009409T patent/PT3318565T/pt unknown
- 2014-11-20 PL PL17200940T patent/PL3318565T3/pl unknown
- 2014-11-20 EP EP14816404.9A patent/EP3077395B1/en active Active
- 2014-12-03 US US14/559,294 patent/US9617258B2/en active Active
- 2014-12-03 UY UY0001035861A patent/UY35861A/es active IP Right Grant
- 2014-12-04 AR ARP140104517A patent/AR099363A1/es active IP Right Grant
- 2014-12-04 TW TW103142238A patent/TWI548636B/zh active
2015
- 2015-04-23 NO NO15721089A patent/NO3134430T3/no unknown
2016
- 2016-05-20 CL CL2016001216A patent/CL2016001216A1/es unknown
- 2016-05-20 PH PH12016500938A patent/PH12016500938B1/en unknown
- 2016-06-03 DO DO2016000124A patent/DOP2016000124A/es unknown
- 2016-06-03 GT GT201600098A patent/GT201600098A/es unknown
- 2016-06-03 SV SV2016005209A patent/SV2016005209A/es unknown
- 2016-06-03 NI NI201600075A patent/NI201600075A/es unknown
- 2016-06-05 IL IL246038A patent/IL246038B/en active IP Right Grant
2017
- 2017-03-01 US US15/446,500 patent/US11111242B2/en active Active
- 2017-08-08 JP JP2017152997A patent/JP2018008996A/ja active Pending
- 2017-11-27 HR HRP20171846TT patent/HRP20171846T1/hr unknown
- 2017-12-18 CY CY20171101325T patent/CY1119778T1/el unknown
2021
- 2021-05-11 CY CY20211100402T patent/CY1124793T1/el unknown
- 2021-05-13 HR HRP20210770TT patent/HRP20210770T1/hr unknown
- 2021-08-04 US US17/393,463 patent/US12077533B2/en active Active
2023
- 2023-10-03 NL NL301245C patent/NL301245I2/nl unknown
- 2023-11-03 FR FR23C1042C patent/FR23C1042I2/fr active Active
- 2023-11-14 HU HUS2300040C patent/HUS2300040I1/hu unknown
- 2023-11-22 FI FIC20230035C patent/FIC20230035I1/fi unknown
2024
- 2024-01-09 NO NO2024001C patent/NO2024001I1/no unknown
- 2024-02-09 CY CY2024002C patent/CY2024002I1/el unknown

Also Published As

Publication number	Publication date
TW201524977A (zh)	2015-07-01
SV2016005209A (es)	2018-04-11
NZ720092A (en)	2019-05-31
ES2871524T3 (es)	2021-10-29
MD20160058A2 (ro)	2016-11-30
GT201600098A (es)	2019-10-17
UA117040C2 (uk)	2018-06-11
MA39092B1 (fr)	2018-09-28
AU2014358792B2 (en)	2017-06-08
CA2932425E (en)	2015-06-11
MX2016007156A (es)	2016-07-21
CA2932425A1 (en)	2015-06-11
PT3318565T (pt)	2021-05-28
CR20160250A (es)	2016-09-19
US12077533B2 (en)	2024-09-03
RS61897B9 (sr)	2021-09-30
AR099363A1 (es)	2016-07-20
LT3318565T (lt)	2021-06-25
EP3318565A1 (en)	2018-05-09
IL246038B (en)	2020-10-29
MD4649C1 (ro)	2020-04-30
CA2932425C (en)	2018-07-17
FR23C1042I1 (fr)	2023-12-29
TN2016000227A1 (fr)	2017-10-06
CU24396B1 (es)	2019-04-04
UY35861A (es)	2015-07-31
US20170247372A1 (en)	2017-08-31
NL301245I2 (nl)	2023-11-20
CY1124793T1 (el)	2022-11-25
CN106061973B (zh)	2019-07-09
CN107417684A (zh)	2017-12-01
BR112016012262A2 (pt)	2020-06-30
CY2024002I2 (el)	2024-09-20
JP2018008996A (ja)	2018-01-18
JP6192839B2 (ja)	2017-09-06
IL246038A0 (en)	2016-08-02
FIC20230035I1 (fi)	2023-11-22
DK3077395T3 (en)	2018-01-02
AU2014358792A1 (en)	2016-06-02
PE20161246A1 (es)	2016-11-25
PT3077395T (pt)	2018-01-03
MD4649B1 (ro)	2019-09-30
SI3077395T1 (en)	2018-03-30
FR23C1042I2 (fr)	2024-11-15
ES2654051T3 (es)	2018-02-12
MY187446A (en)	2021-09-22
HRP20210770T1 (hr)	2021-06-25
BR112016012262B1 (pt)	2021-04-13
PH12016500938A1 (en)	2016-06-27
DK3318565T3 (da)	2021-05-25
CU20160077A7 (es)	2017-01-10
US11111242B2 (en)	2021-09-07
HUS2300040I1 (hu)	2023-12-28
EP3077395A1 (en)	2016-10-12
CY2024002I1 (el)	2024-09-20
ME02883B (me)	2018-04-20
CN106061973A (zh)	2016-10-26
GEP20186840B (en)	2018-04-10
LT3077395T (lt)	2018-02-12
HUE035264T2 (hu)	2018-05-02
RS56728B1 (sr)	2018-03-30
NI201600075A (es)	2016-08-09
EA030472B1 (ru)	2018-08-31
JP2016539137A (ja)	2016-12-15
KR20160092012A (ko)	2016-08-03
KR101930603B1 (ko)	2018-12-18
AP2016009269A0 (en)	2016-06-30
NO3134430T3 (no)	2018-08-18
AU2014358792C1 (en)	2021-08-26
EP3077395B1 (en)	2017-11-15
RS61897B1 (sr)	2021-06-30
US20230009153A1 (en)	2023-01-12
EP3318565B1 (en)	2021-04-14
PL3318565T3 (pl)	2021-10-04
US9617258B2 (en)	2017-04-11
WO2015083028A1 (en)	2015-06-11
PL3077395T3 (pl)	2018-04-30
PH12016500938B1 (en)	2016-06-27
MA39092A1 (fr)	2018-06-29
CY1119778T1 (el)	2018-06-27
EA201600373A1 (ru)	2016-10-31
MX368464B (es)	2019-10-02
DOP2016000124A (es)	2016-10-31
US20150158864A1 (en)	2015-06-11
CL2016001216A1 (es)	2017-01-20
HUE054560T2 (hu)	2021-09-28
HRP20171846T1 (hr)	2018-01-12
SI3318565T1 (sl)	2021-07-30
TWI548636B (zh)	2016-09-11

Publication	Publication Date	Title
NO2024001I1 (no)	2024-01-09	Ritlecitinib, or a pharmaceutically acceptable salt thereof
NO2022004I1 (no)	2022-02-01	abrocitinib, or a pharmaceutically acceptable salt thereof
NO2024042I1 (no)	2024-09-30	Iptacopan or a pharmaceutically acceptable salt thereof
NO2023043I1 (no)	2023-12-01	Mavacamten or a pharmaceutically acceptable salt thereof
NO2022005I1 (no)	2022-02-03	Zanubrutinib or a pharmaceutically acceptable salt thereof
NO2022010I1 (no)	2022-04-07	ripretinib, or a pharmaceutically acceptable salt thereof
NO2021034I1 (no)	2021-09-09	pemigatinib or a pharmaceutically acceptable salt thereof
NO2021035I1 (no)	2021-09-10	Risdiplam or a pharmaceutically acceptable salt thereof
NO2021041I1 (no)	2021-09-20	remimazolam or a pharmaceutically acceptable salt thereof
NL301286I2 (nl)	2024-09-18	Danicopan, of een farmaceutisch aanvaardbaar zout ervan
NO2022044I1 (no)	2022-10-27	daridorexant eller et farmasøytisk akseptabelt salt derav, spesielt daridorexant hydroklorid
NO2022009I1 (no)	2022-04-05	Lumasiran, optionally in the form of a salt
NL301149I2 (nl)	2022-11-24	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
LUC00083I2 (en)	2018-10-15	Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium
NO2024009I1 (no)	2024-03-06	Gefapixant, or a pharmaceutically acceptable salt thereof
NO2020029I1 (no)	2020-08-26	Givosiran eller et farmasøytisk akseptabelt salt derav
NO2022058I1 (no)	2022-12-16	Capmatinib or a pharmaceutically acceptable salt thereof
HUE037275T2 (hu)	2018-08-28	Gyógyszer-kombináció
BR302014001376S1 (pt)	2015-05-19	Configuração aplicada em bolsa.
ZA201603624B (en)	2019-04-24	Urea derivative or pharmacologically acceptable salt thereof
LT3077047T (lt)	2019-08-26	Aramcholio druskos
DK2975030T3 (da)	2020-08-31	Dihydropyridazin-3,5-dion-derivat
FR3010437B1 (fr)	2016-02-19	Serrure a mortaiser reglable
PT2980085T (pt)	2018-04-09	Compostos farmaceuticamente activos
FI20135236A (fi)	2014-08-15	Haudutin